Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?

Pfizer’s (PFE) non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). The trend is expected to have continued in the fourth quarter.In the past year, Pfizer’s stock has declined 0.2% compared with a decrease of 2.5% for the industry. Image Source: Zacks Investment ResearchDrug Sales Estimates: Vyndaqel, Pr ...